Nkarta stock soars 112% after FDA clears cell therapy to go beyond cancer into lupus

Nkarta wants cell therapy to go beyond cancer and has been given the FDA green light to move forward with a CAR NK candidate in human trials for lupus—news that sent the company’s stock soaring 112%. “Autoimmune patients have limited options these days, and those options that they have are often…#nkarta #fda #autoimmune #paulhastings #fiercebiotech #nkx019 #davidshook #fierce #sle #shook
Source: Reuters: Health - Category: Consumer Health News Source Type: news